Stem cell transplants have been widely used as a treatment for cancer since the 1960s. In 2010, the FDA approved Provenge, a product designed to treat late-stage prostate cancer. Cell therapy products designed for treating cancer are expected to be a growth segment for the industry over the next five years.

According to the Alliance for Regenerative Medicine’s 2013 annual report, cell therapy for cancer treatments makes up 32 percent of all cell therapy products that are in the late-stage trial phase.